Hiv/Aids: the Effect on the Global Community.
HIV/AIDS: The effect on the global community.
According to the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS)
At the end of 1999; an estimated 34.3 million people were living with HIV/AIDS. Most of the people living with HIV, 95% of the global total, live in developing countries.” Examples of the impact of HIV/AIDS in Africa, Asia, Latin America, the Caribbean, and the Newly Independent States provide insight into the demographics, modes of exposure, treatment and prevention options, and the economic effect of the epidemic on the global community. The epidemic in each region of the world is influenced by the specific risk factors that are associated with the spread of HIV/AIDS and the responses that have evolved to address it. These influences are important in developing HIV/AIDS policies and programs to effectively address the global pandemic. (Gayle, H. & Hill, G. 2001).
Gayle (2001) “The HIV/AIDS pandemic has profoundly affected the economy, the work force, individual workers and their families, health care expenditures, the cost of labor, and savings and investments. AIDS is the second leading cause of death among adults in developing countries. It is projected that HIV will be responsible for almost 40% of all deaths from infectious diseases by 2020. AIDS also has costly consequences, especially for the poor. Because AIDS affects people during their most productive years, it has negative consequences for worker productivity, family income, and national revenues. As the pandemic evolves, it widens the gap between available resources and the needs for care. Annual medical costs in African countries during 1990 to 1993 ranged from US$210 (Malawi) to US$936 (Zimbabwe) per person in industrialized countries during those years, costs ranged from US$20,000 (United Kingdom) to US$57,000 (Switzerland) per person. The overall cost of care in industrialized countries has increased steadily because of the increased number of
According to the World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS)
At the end of 1999; an estimated 34.3 million people were living with HIV/AIDS. Most of the people living with HIV, 95% of the global total, live in developing countries.” Examples of the impact of HIV/AIDS in Africa, Asia, Latin America, the Caribbean, and the Newly Independent States provide insight into the demographics, modes of exposure, treatment and prevention options, and the economic effect of the epidemic on the global community. The epidemic in each region of the world is influenced by the specific risk factors that are associated with the spread of HIV/AIDS and the responses that have evolved to address it. These influences are important in developing HIV/AIDS policies and programs to effectively address the global pandemic. (Gayle, H. & Hill, G. 2001).
Gayle (2001) “The HIV/AIDS pandemic has profoundly affected the economy, the work force, individual workers and their families, health care expenditures, the cost of labor, and savings and investments. AIDS is the second leading cause of death among adults in developing countries. It is projected that HIV will be responsible for almost 40% of all deaths from infectious diseases by 2020. AIDS also has costly consequences, especially for the poor. Because AIDS affects people during their most productive years, it has negative consequences for worker productivity, family income, and national revenues. As the pandemic evolves, it widens the gap between available resources and the needs for care. Annual medical costs in African countries during 1990 to 1993 ranged from US$210 (Malawi) to US$936 (Zimbabwe) per person in industrialized countries during those years, costs ranged from US$20,000 (United Kingdom) to US$57,000 (Switzerland) per person. The overall cost of care in industrialized countries has increased steadily because of the increased number of
References: Gayle, Helene, D. (2001). Clinical Microbiology Reviews. PubMed Central. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC88977